Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2013 | short review | Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013

ASH Annual Meeting 2012—Chronic Myeloid Leukemia Update

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2013
Autor:
Prof. Dr. Andreas L. Petzer

Abstract

At the recent ASH meeting, updated 4 year results on the use of the second-generation tyrosine kinase inhibitor nilotinib compared with imatinib were presented and they demonstrated superiority in achieving faster and deeper molecular responses for nilotinib compared to imatinib. A rapid decrease in BCR-ABL transcripts of ≤ 10 % BCR-ABL IS at 3 months is associated with a statistically significantly superior overall survival regardless which tyrosine kinase inhibitor was used (nilotinib, dasatinib, and imatinib). By using a second-generation tyrosine kinase inhibitor, however, the chance to achieve ≤ 10 % BCR-ABL IS at 3 months is significantly higher. Some data also indicate that some caution should be taken for new and so far unknown potential side effects of second-generation tyrosine kinase inhibitors.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013 Zur Ausgabe